ClinicalTrials.gg
Active, not recruitingNCT05763290Updated Aug 28, 2026

Childhood Cancer Survivors' Affective Response to Exercise

An observational study in ALL, Childhood and Acute Lymphoblastic Leukemia, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by St. Jude Children's Research Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
125
Ages
18 Years to 39 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.

Enrollment
8th of 13
125 · median 165
Started
2023
with 1 other
Observational
13 of 70
2 open now
Primary completion
2027-02
later than 11 of 24 live
Registered
57th of 70
by date

Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 8th largest by enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 13 observational ones, reaches primary completion later than 11 of the 24 other live ones, and was the 57th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 39 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the feasibility of administering the Personalized Single-Category Implicit Association Test (PSC-IAT) to young adult survivors of childhood cancer.

Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.

Read the detailed description

Researchers at St. Jude Children's Research Hospital want to learn about the measurement of implicit association bias towards or against exercise in childhood cancer survivors. Additionally, researchers want to learn more about the physical and emotional experience of exercise from our survivors.

The plan for this study is to administer single category implicit association tests (PSC-IAT's) to participants during on campus SJLIFE testing and use this data to determine the feasibility of this tool's use in survivors of childhood cancer without cognitive impairment. This study will also administer the Behavioral Regulations in Exercise Questionnaire (BREQ-2)37 to participants as a construct validity check to the PSC-IAT.

The procedures include PSC-IAT and BREQ-2 tests (before and after strenuous exercise as part of the SJLIFE protocol) and a qualitative interview. These will be in addition to standard components of the SJLIFE on-campus visit.

03

Conditions studied

  • ALL, Childhood
  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include survivors from the SJLIFE cohort from the ALL diagnostic group (treated without cranial radiation therapy (CRT). This group was chosen because of the prevalence of ALL in childhood cancer diagnoses, and to attempt to prevent potential difficulties with the cognitive task due to cognitive impairment from CRT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants enrolled in St. Jude Lifetime Cohort (SJLIFE) aged 18-39 years at completion of on campus visit
  • Primary diagnosis of acute lymphoblastic leukemia (ALL)
  • No cranial radiation therapy (CRT) as part of treatment for ALL
  • Identify as physically inactive (do not meet Centers for Disease Control and Prevention (CDC) guidelines of 150 minutes of moderate physical activity per week or 75 minutes of vigorous physical activity per week)
  • Women who are not currently pregnant

Exclusion criteria

Exclusion Criteria:

  • Individuals who cannot speak, read, and/or understand English.
  • Individuals with an estimated IQ of \<70 and/or per PI discretion
  • Individuals with any to stress testing (i.e. cardiovascular complications)
  • Women who are currently pregnant
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
125 participants (actual)
Patient registry
No

Interventions

  • OtherAffective Response to Exercise

    Participants will perform a total of three trials of a cognitive task before and after their scheduled SJLIFE cardiovascular stress testing. Participants will then be asked to participate in a qualitative interview about the cognitive task tool and body sensations and emotions experienced during exercise.

06

What researchers measure

Primary outcomes

  1. Implicit Association Bias Testing

    Participants' implicit associations with exercise will be measured using the Personalized Single-Category Implicit Association test (PSC-IAT).

    Time frame: Before and after Cardiovascular Stress Testing at Baseline

  2. Behavioral Regulation of Exercise Questionnaire (BREQ-2):

    The Behavioral Regulation of Exercise Questionnaire (BREQ-2) will be administered once to participants in this study to assess trait-level affective motivation.

    Time frame: Before and after Cardiovascular Stress Testing at Baseline

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Feb 2027, 47 months after the start.

Of 145 non-industry observational studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 143. This study's planned 47 months is close to that.

Counting every sponsor, half of 163 studies reached it within 49 months; a quarter within 22 and three quarters within 142.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2023
First posted
Mar 10, 2023
StartActual
Mar 22, 2023
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2030
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05763290
Responsible party
Sponsor
First posted
Mar 10, 2023
Start date
Mar 22, 2023
Primary completion
Feb 2027 (estimated)
Completion
Feb 2030 (estimated)
Last update
Aug 28, 2026

Study contacts

Kirsten Ness, PhD
principal investigator · St. Jude Children's Research Hospital
Deo Srivastava, PhD
principal investigator · St. Jude Children's Research Hospital
Lisa Jacola, PhD, ABPP-CN2
principal investigator · St. Jude Children's Research Hospital
Rachel Webster, PhD
principal investigator · St. Jude Children's Research Hospital
Tara Brinkman, PhD
principal investigator · St. Jude Children's Research Hospital
Kevin Krull, PhD
principal investigator · St. Jude Children's Research Hospital
Melissa Hudson, MD
principal investigator · St. Jude Children's Research Hospital
Leslie Robinson, PhD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion